{
    "ticker": "TSHA",
    "name": "TSHA Gene Therapies, Inc.",
    "description": "TSHA Gene Therapies, Inc. is a biotechnology company focused on developing innovative gene therapies for the treatment of neurological diseases. Founded in 2020 and headquartered in Durham, North Carolina, TSHA aims to transform the lives of patients through its advanced gene therapy platform. The company's proprietary technology is designed to overcome the challenges of delivering genetic material to the central nervous system, which has been a significant barrier in treating neurological disorders. TSHA is committed to developing therapies that can provide lasting benefits for patients with conditions such as Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative diseases. With a robust pipeline of product candidates, including its lead program targeting Huntington's disease, TSHA is at the forefront of the gene therapy revolution. The company collaborates with leading academic institutions and industry partners to advance its research and clinical programs. TSHA's mission is to provide groundbreaking therapies that can address unmet medical needs and improve patient outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Durham, North Carolina, USA",
    "founded": "2020",
    "website": "https://www.tshagenetherapies.com",
    "ceo": "Seth H. R. Williams",
    "social_media": {
        "twitter": "https://twitter.com/TSHAGeneTherapy",
        "linkedin": "https://www.linkedin.com/company/tsha-gene-therapies"
    },
    "investor_relations": "https://investors.tshagenetherapies.com",
    "key_executives": [
        {
            "name": "Seth H. R. Williams",
            "position": "CEO"
        },
        {
            "name": "Gordon F. T. K. Lee",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapy",
            "products": [
                "TSHA-101",
                "TSHA-102"
            ]
        }
    ],
    "seo": {
        "meta_title": "TSHA Gene Therapies, Inc. | Innovative Gene Therapies for Neurological Diseases",
        "meta_description": "TSHA Gene Therapies, Inc. is dedicated to developing groundbreaking gene therapies for neurological conditions. Learn more about our innovative pipeline and commitment to patients.",
        "keywords": [
            "TSHA Gene Therapies",
            "Gene Therapy",
            "Neurological Diseases",
            "Huntington's Disease",
            "ALS",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What does TSHA Gene Therapies focus on?",
            "answer": "TSHA Gene Therapies focuses on developing innovative gene therapies for the treatment of neurological diseases."
        },
        {
            "question": "Who is the CEO of TSHA Gene Therapies?",
            "answer": "Seth H. R. Williams is the CEO of TSHA Gene Therapies, Inc."
        },
        {
            "question": "Where is TSHA Gene Therapies headquartered?",
            "answer": "TSHA Gene Therapies is headquartered in Durham, North Carolina, USA."
        },
        {
            "question": "What are the main products of TSHA?",
            "answer": "TSHA's main products include gene therapy candidates such as TSHA-101 and TSHA-102."
        },
        {
            "question": "When was TSHA Gene Therapies founded?",
            "answer": "TSHA Gene Therapies was founded in 2020."
        }
    ],
    "competitors": [
        "AVXL",
        "CRSP",
        "SGMO",
        "FOLD"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "VRTX",
        "BMRN"
    ]
}